• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System

    4/7/25 7:01:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email

    Novel hybrid LTS-HTS superconducting magnet enables high-resolution for liquids and solids ultra-high field NMR research in biomolecular and advanced materials sciences

    At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world's first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. This first-of-a-kind ultra-high field magnet and spectrometer pushes the boundaries of what is possible in the field of NMR research and opens a new chapter of ultra-high field NMR with even higher dispersion and resolution.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407030056/en/

    The 1.3 GHz first-of-a-kind high-resolution UHF NMR spectrometer in Bruker's UHF facility in Fällanden, Switzerland

    The 1.3 GHz first-of-a-kind high-resolution UHF NMR spectrometer in Bruker's UHF facility in Fällanden, Switzerland

    Building on the success of its 1.0-1.2 GHz systems, Bruker's 1.3 GHz NMR spectrometer offers unprecedented resolution and sensitivity, enabling scientists to study complex biomolecular systems and advanced materials in greater detail. The first-of-a-kind superconducting and persistent standard-bore NMR magnet has a field strength of 30.5 Tesla (T) and incorporates a novel ReBCO high-temperature superconductor (HTS) insert, generating even higher magnetic fields. The novel 1.3 GHz magnet extends Bruker's innovative LTS-HTS hybrid magnet architecture. Despite higher field, the 1.3 GHz magnet maintains the same physical dimensions and cryogen consumption as Bruker's 1.2 GHz magnets, with a slightly increased stray field radius.

    Applications testing at 1.3 GHz proton frequency was conducted using five different NMR probe configurations: a 3 mm TXI liquids room-temperature probe, a 5 mm TXO liquids CryoProbe, a 111 kHz (0.7 mm) HCN solid-state magic-angle spinning (MAS) probe, a 42 kHz (1.9 mm) solid-state MAS probe optimized for materials research, and the new ultra-fast spinning 160 kHz (0.4 mm) HCN solid-state MAS probe, the latest innovations in solid-state NMR for the study of biological systems. These tests confirmed the applicability of the 1.3 GHz NMR first-of-a-kind spectrometer, yielding high-resolution liquids and solids NMR spectra at 1.3 GHz. The results demonstrated increased resolution and sensitivity, highlighting the potential for groundbreaking biomolecular and materials research.

    The increased magnet field strength particularly benefits spectroscopy of bio-macromolecules lacking dispersion, such as carbohydrates, glycoproteins, RNA, and intrinsically disordered proteins (IDPs) without secondary and tertiary structures. Direct 13C and 15N detection of IDPs shows the gain of 1.3 GHz sensitivity, offering new strategies to obtain atomic resolution with respect to dynamics and function. In solid state, UHF NMR is crucial for studying quadrupolar nuclei, where the increased field leads to narrower spectral lines due to the inverse relationship between the breadth of the quadrupolar pattern and the field strength. Additionally, the chemical shift interaction grows linearly with the field, enhancing the ability to measure chemical shift tensors using UHF systems. These technological advancements are driving exciting breakthroughs in both material science and biological science.

    "Achieving 1.3 GHz is yet another testament to Bruker's commitment to innovation," said Dr. Falko Busse, President of the Bruker BioSpin Group. "We are confident that our high-resolution GHz-class NMRs enable researchers to advance their scientific understanding of complex biomolecular systems, and also provide substantial benefits for advanced materials science research, particularly in molecules and materials incorporating chemical elements with quadrupolar and low-gamma nuclei."

    "We are thrilled to be among the first scientists to experiment with the 1.3 GHz NMR spectrometer," said Dr. Takanori Kigawa from the Center for Integrative Medical Sciences of the RIKEN Yokohama Institute, Japan, a leading researcher in structural biology. "The gain in resolution and sensitivity is truly remarkable. We were blown away by the level of detail we observe in our protein and nucleic acid samples, which opens up new opportunities for our research in biological systems."

    Dr. Pierre Florian, materials science researcher at CEMHTI-CNRS Orléans, France, who ran solid-state samples for characterization, stated: "I am very impressed with the first experiments carried out on the 1.3 GHz spectrometer. This technology dramatically improves our ability to resolve different types of atomic environments in complex materials and also offers unprecedented sensitivity."

    About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR)

    Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250407030056/en/

    Investor Contact:

    Joe Kostka

    Director - Investor Relations

    Bruker Corporation

    T: +1 (978) 313-5800

    E: [email protected]

    Media Contact:

    Markus Ziegler

    Sr. Director and Head of Group Marketing

    Bruker BioSpin

    T: +49 172 373-3531

    E: [email protected]

    Get the next $BRKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    12/10/2025$60.00Peer Perform → Outperform
    Wolfe Research
    12/9/2025$40.00Sell
    Goldman
    11/20/2025$60.00Buy
    Rothschild & Co Redburn
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    More analyst ratings

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59 FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83 Bruker initiates FY26 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's Presid

    2/12/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

    New iNTApharma system enables rapid, native‑state size and concentration measurements with single‑particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticle populations without labeling or chemical modifications.

    2/9/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

    At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enables lab managers to operationalize autonomous, AI‑orchestrated experimentation through vendor‑agnostic integration that unites modular precision automation, scientific analysis and lab management software, complete lab digitization a

    2/9/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $98,400 worth of shares (2,000 units at $49.20) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/16/26 4:15:05 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 7,000 shares at a strike of $22.19 and sold $385,000 worth of shares (7,000 units at $55.00) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/13/26 4:15:06 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Phillips Jack

    3 - BRUKER CORP (0001109354) (Issuer)

    1/9/26 6:19:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00

    12/10/25 9:02:11 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Bruker with a new price target

    Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00

    12/9/25 8:43:14 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rothschild & Co Redburn initiated coverage on Bruker with a new price target

    Rothschild & Co Redburn initiated coverage of Bruker with a rating of Buy and set a new price target of $60.00

    11/20/25 8:06:38 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    SEC Filings

    View All

    Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    2/12/26 7:00:26 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - BRUKER CORP (0001109354) (Filer)

    1/12/26 12:00:24 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    12/9/25 10:10:52 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59 FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83 Bruker initiates FY26 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's Presid

    2/12/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Quarterly Preferred Stock Dividend

    Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 2026. About Bruker Corporation – Leader of the Post-Genomic Era Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's hi

    2/5/26 4:05:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Date and Time of Fourth Quarter 2025 Earnings Release and Webcast

    Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2025 financial results before market opening on Thursday, February 12, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2025 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43

    2/5/26 8:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials